<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103063</url>
  </required_header>
  <id_info>
    <org_study_id>A0661158</org_study_id>
    <nct_id>NCT01103063</nct_id>
  </id_info>
  <brief_title>Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa</brief_title>
  <official_title>A Phase 3, Open Label, Randomized, Comparative Study To Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to establish superiority of AZCQ over SP in protective efficacy for
      IPTp as measured by the proportion of subjects with sub-optimal pregnancy outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After interim analysis of efficacy data by an External Data Monitoring Committee, this study
      was terminated. Investigators were notified on 22 Aug 2013. There were no safety concerns
      that led to this termination.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Participants With Sub-optimal Pregnancy Outcome in Intent-to-Treat (IIT) Population</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with low birth weight (LBW) (&lt;2,500 g), premature births (&lt;37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (&gt;28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sub-optimal Pregnancy Outcome in Efficacy Analyzable Per Protocol (PP) Population</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with LBW (&lt;2,500g), premature births (&lt;37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (&gt;28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Neonates With LBW (&lt;2500 g) in ITT Population</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>LBW was defined as live birth weight &lt;2500 g (up to and including 2499 g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Neonates With LBW (&lt;2500 g) in Efficacy Analyzable PP Population</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>LBW was defined as live birth weight &lt;2500 g (up to and including 2499 g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Severe Maternal Anemia (Hemoglobin [Hb] &lt;8 g/dL) at 36-38 Weeks of Gestation</measure>
    <time_frame>At 36-38 weeks of gestation.</time_frame>
    <description>Severe maternal anemia was defined as Hb &lt;8 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Maternal Anemia (Hb &lt;11 g/dL) at 36-38 Weeks of Gestation</measure>
    <time_frame>At 36-38 weeks of gestation.</time_frame>
    <description>Anemia was defined as Hb &lt;11 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Placental Parasitemia at Delivery</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>Participants with placental parasitemia at delivery were diagnosed using Placental blood smear at birth from participants who deliver at hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Placental Malaria at Delivery Based on Histology</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>Participants positive for placental malaria at delivery were evaluated based on placental histology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexually Transmitted Infection (STI) Episodes Per Participant</measure>
    <time_frame>Approximately 40 weeks of gestational age .</time_frame>
    <description>Number of episodes of sexually transmitted infection episodes per participant were noted. The STI's including Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis, from first dose to delivery (diagnosis was based on clinical presentation and lab results).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sub-optimal Pregnancy Outcome Including Neonatal Death and Congenital Malformation</measure>
    <time_frame>Approximately 40 weeks of gestational age.</time_frame>
    <description>Sub-optimal pregnancy outcome including neonatal deaths and congenital malformations, defined as any of the following: live-borne neonate (singleton) with low birth-weight (or LBW for short, defined as live birth weight &lt;2,500g), premature birth (&lt;37 weeks), abortion (≤28 weeks), still birth (&gt;28 weeks), neonatal death, congenital malformation, lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 36-38 Weeks of Gestation in Hb Concentration.</measure>
    <time_frame>Baseline, at 36-38 weeks of gestation.</time_frame>
    <description>Change from Baseline to 36-38 weeks of gestation in Hb concentration was noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Neonates With Congenital Abnormalities at Birth</measure>
    <time_frame>Approximately 40 weeks of gestational age.</time_frame>
    <description>Neonates with congenital abnormalities at birth were noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Perinatal or Neonatal Deaths</measure>
    <time_frame>Day 28 after delivery.</time_frame>
    <description>Percentage of perinatal or neonatal deaths were noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth Weight of Live Borne Neonate</measure>
    <time_frame>Approximately 40 weeks of gestational age.</time_frame>
    <description>Birth weight of live borne neonates were calculated in grams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Symptomatic Malaria Per Participant From First Intermittent Preventive Treatment of Falciparum Dose to Delivery</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>This outcome measure determined if an episode of malaria started within the time period of first dose to delivery. Clinical episode of malaria was determined if the participant presented with clinical symptoms of malaria (fever &gt;37.5°C, oral) and diagnosed (either by rapid diagnostic tests or microscopy) with malaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Additional Treatment for Symptomatic Malaria From First Dose to Delivery</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>This outcome measure evaluated the participants requiring additional treatments for malaria during the study period following the first dose (diagnosed based on clinical presentation and/or lab test results).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Peripheral Parasitemia at 36-38 Weeks of Gestation</measure>
    <time_frame>At 36-38 weeks of gestation</time_frame>
    <description>This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at 36-38 weeks of gestation. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Peripheral Parasitemia at Delivery</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cord Blood Parasitemia at Delivery</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>This outcome measure evaluated the percentage of participants positive for cord blood parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sexually Transmitted Infections From First Dose to 36-38 Weeks of Gestation</measure>
    <time_frame>Upto 36-38 weeks of gestation</time_frame>
    <description>Sexual transmitted disease included Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis infections. This was diagnosed based on clinical presentation prior to Week 36-38 and/or lab test results between Week 36-38.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Chlamydia Trachomatis Infection at 36-38 Weeks of Gestation</measure>
    <time_frame>At 36-38 weeks of gestation</time_frame>
    <description>Participants positive for Chlamydia trachomatis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Neisseria Gonorrhoeae Infection at 36-38 Weeks of Gestation</measure>
    <time_frame>At 36-38 weeks of gestation</time_frame>
    <description>Participants positive for Neisseria gonorrhoeae infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treponema Pallidum Infection at 36-38 Weeks of Gestation</measure>
    <time_frame>At 36-38 weeks of gestation</time_frame>
    <description>Participants positive for Treponema pallidum infection was diagnosed based on laboratory result at 36-38 weeks of gestation. Treponema Pallidum particle Agglutination Assay was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Trichomonas Vaginalis Infection at 36-38 Weeks of Gestation</measure>
    <time_frame>At 36-38 weeks of gestation</time_frame>
    <description>Participants positive for Trichomonas vaginalis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the laboratory test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Bacterial Vaginosis Infection at 36-38 Weeks of Gestation.</measure>
    <time_frame>At 36-38 weeks of gestation</time_frame>
    <description>Bacterial vaginosis was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the Gram staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Neonates With Ophthalmia Neonatorum at Birth Period</measure>
    <time_frame>Approximately 40 weeks of gestational age</time_frame>
    <description>Ophthalmia neonatorum was diagnosed at birth. The laboratory diagnosis was performed among neonates with purulent discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Bacterial Infections Including Pneumonia and Other Lower Respiratory Tract Infections From First Dose to Delivery</measure>
    <time_frame>Up to approximately 40 weeks of gestational age</time_frame>
    <description>Participants positive for bacterial infections including other lower respiratory tract infections were measured anytime from first dose administration to delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-eclampsia From Week 20 to Delivery</measure>
    <time_frame>From Week 20 to approximately 40 weeks of gestational age</time_frame>
    <description>Pre-eclampsia was diagnosed as systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg on two separate readings taken at least 4 hours apart and proteinuria at least 300 mg protein in a 24 hour urine collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasopharyngeal Swabs Positive for Macrolide Resistant Streptococcus Pneumoniae</measure>
    <time_frame>Visits 6 and 7</time_frame>
    <description>This outcome measure evaluated the Streptococcus pneumoniae sensitivity against macrolide antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasopharyngeal Swabs Positive for Penicillin Resistant Streptococcus Pneumoniae</measure>
    <time_frame>Visits 6 and 7</time_frame>
    <description>This outcome measure evaluated the Streptococcus pneumoniae sensitivity against penicillin antibiotics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2891</enrollment>
  <condition>Intermittent Preventive Treatment In Pregnancy (IPTp)</condition>
  <arm_group>
    <arm_group_label>AZCQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin/chloroquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sulfadoxine-pyrimethamine (Fansidar)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin plus chloroquine</intervention_name>
    <description>combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.</description>
    <arm_group_label>AZCQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfadoxine-pyrimethamine</intervention_name>
    <description>Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.</description>
    <arm_group_label>SP</arm_group_label>
    <other_name>Fansidar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women (all gravidae) with ≥14 and ≤26 weeks of gestational age (by
             ultrasound).

          -  Evidence of a personally signed and dated informed consent/assent document. Assent
             will be obtained from subjects &lt;18 years of age.

          -  Subjects who are willing to and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

          -  Subjects who are available for follow up at delivery and on 28 days post delivery.

        Exclusion Criteria:

          -  Age &lt;16 years old or &gt;35 years old.

          -  Multiple gestations as per the ultrasound at screening.

          -  Clinical symptoms of malaria.

          -  Hemoglobin &lt; 8 g/dL (at enrollment).

          -  Any condition requiring hospitalization at enrollment.

          -  History of convulsions, hypertension, diabetes or any other chronic illness that may
             adversely affect fetal growth and viability.

          -  Inability to tolerate oral treatment in tablet form.

          -  Known allergy to the study drugs (azithromycin, chloroquine, and
             sulfadoxine-pyrimethamine) or to any macrolides or sulphonamides.

          -  Requirement to use medication during the study that might interfere with the
             evaluation of the study drug eg, trimethoprim-sulfamethoxazole use in subjects
             positive for HIV infection.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation.

          -  Evidence of current obstetric complications that may adversely impact the pregnancy
             and/or fetal outcomes, including presence of congenital anomalies, placenta previa or
             abruption.

          -  Known severe Sickle Cell (SS) disease or Sickle Hemoglobin C (SC) anemia.

          -  Known family history of prolonged QT Syndrome, serious ventricular arrhythmia, or
             sudden cardiac death.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Santé d'AHOUANSORI-AGUE</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bethesda</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siaya District Hospital</name>
      <address>
        <city>Siaya</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zomba Central Hospital</name>
      <address>
        <city>Zomba</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teule Hospital</name>
      <address>
        <city>Muheza</city>
        <state>Tanga</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugando Medical Centre</name>
      <address>
        <city>Mwanza</city>
        <zip>1903</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyamagana District Hospital, c/o National Institute for Medical Research, Mwanza Centre</name>
      <address>
        <city>Mwanza</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyamagana District Hospital</name>
      <address>
        <city>Mwanza</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mulago Hospital Complex</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Tanzania</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661158&amp;StudyName=Evaluate%20Azithromycin%20Plus%20Chloroquine%20And%20Sulfadoxine%20Plus%20Pyrimethamine%20Combinations%20For%20Intermittent%20Preventive%20Treatment%20Of%20Falciparum%20Malar</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <results_first_submitted>August 25, 2014</results_first_submitted>
  <results_first_submitted_qc>August 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2014</results_first_posted>
  <last_update_submitted>May 14, 2015</last_update_submitted>
  <last_update_submitted_qc>May 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P. falciparum malaria</keyword>
  <keyword>IPTp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This Phase 3, open label, randomized, parallel group study screened a total of 3259 participants in 6 sites. A total of 2891 were treated either with azithromycin+chloroquine or sulfadoxine+pyrimethamine.</recruitment_details>
      <pre_assignment_details>Pregnant women (all gravidae) with ≥14 and ≤26 weeks of gestational age were to be enrolled in this study. Approximately half of the participants were to be primigravidae and secundigravidae pregnant women since they had a higher risk for suboptimal pregnancy outcomes due to malaria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Azithromycin + Chloroquine</title>
          <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
        </group>
        <group group_id="P2">
          <title>Sulfadoxine + Pyrimethamine</title>
          <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1446"/>
                <participants group_id="P2" count="1445"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="969"/>
                <participants group_id="P2" count="1024"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="477"/>
                <participants group_id="P2" count="421"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="326"/>
                <participants group_id="P2" count="342"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azithromycin + Chloroquine</title>
          <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
        </group>
        <group group_id="B2">
          <title>Sulfadoxine + Pyrimethamine</title>
          <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1446"/>
            <count group_id="B2" value="1445"/>
            <count group_id="B3" value="2891"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.3" spread="4.5"/>
                    <measurement group_id="B2" value="23.3" spread="4.6"/>
                    <measurement group_id="B3" value="23.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1446"/>
                    <measurement group_id="B2" value="1445"/>
                    <measurement group_id="B3" value="2891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Participants With Sub-optimal Pregnancy Outcome in Intent-to-Treat (IIT) Population</title>
        <description>Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with low birth weight (LBW) (&lt;2,500 g), premature births (&lt;37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (&gt;28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Participants With Sub-optimal Pregnancy Outcome in Intent-to-Treat (IIT) Population</title>
          <description>Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with low birth weight (LBW) (&lt;2,500 g), premature births (&lt;37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (&gt;28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.16" lower_limit="23.89" upper_limit="28.43"/>
                    <measurement group_id="O2" value="23.67" lower_limit="21.48" upper_limit="25.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12237</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint)</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.11</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.0647</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sub-optimal Pregnancy Outcome in Efficacy Analyzable Per Protocol (PP) Population</title>
        <description>Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with LBW (&lt;2,500g), premature births (&lt;37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (&gt;28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>Subset of ITT participants: outcome or withdrawal occurred on or before 8/27/2013 (date of study termination), compliant with study medication, birth weight measured on or before 7 days after birth if not already a failure, and did not switch to standard of care.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sub-optimal Pregnancy Outcome in Efficacy Analyzable Per Protocol (PP) Population</title>
          <description>Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with LBW (&lt;2,500g), premature births (&lt;37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (&gt;28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
          <population>Subset of ITT participants: outcome or withdrawal occurred on or before 8/27/2013 (date of study termination), compliant with study medication, birth weight measured on or before 7 days after birth if not already a failure, and did not switch to standard of care.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="1176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.38" lower_limit="8.57" upper_limit="12.19"/>
                    <measurement group_id="O2" value="10.12" lower_limit="8.40" upper_limit="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84117</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint)</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1243</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its SE, with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Neonates With LBW (&lt;2500 g) in ITT Population</title>
        <description>LBW was defined as live birth weight &lt;2500 g (up to and including 2499 g).</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Total live births.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Neonates With LBW (&lt;2500 g) in ITT Population</title>
          <description>LBW was defined as live birth weight &lt;2500 g (up to and including 2499 g).</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Total live births.</population>
          <units>Percentage of neonates</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1140"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" lower_limit="3.74" upper_limit="6.28"/>
                    <measurement group_id="O2" value="5.72" lower_limit="4.40" upper_limit="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4428</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.87</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1745</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Neonates With LBW (&lt;2500 g) in Efficacy Analyzable PP Population</title>
        <description>LBW was defined as live birth weight &lt;2500 g (up to and including 2499 g).</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>Subset of ITT participants: outcome or withdrawal occurred on or before 8/27/2013 (date of study termination), compliant with study medication, birth weight measured on or before 7 days after birth if not already a failure, and did not switch to standard of care. N=Total Live Births.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Neonates With LBW (&lt;2500 g) in Efficacy Analyzable PP Population</title>
          <description>LBW was defined as live birth weight &lt;2500 g (up to and including 2499 g).</description>
          <population>Subset of ITT participants: outcome or withdrawal occurred on or before 8/27/2013 (date of study termination), compliant with study medication, birth weight measured on or before 7 days after birth if not already a failure, and did not switch to standard of care. N=Total Live Births.</population>
          <units>Percentage of neonates</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1041"/>
                <count group_id="O2" value="1134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" lower_limit="3.43" upper_limit="6.01"/>
                    <measurement group_id="O2" value="5.21" lower_limit="3.92" upper_limit="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6086</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1882</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Severe Maternal Anemia (Hemoglobin [Hb] &lt;8 g/dL) at 36-38 Weeks of Gestation</title>
        <description>Severe maternal anemia was defined as Hb &lt;8 g/dL.</description>
        <time_frame>At 36-38 weeks of gestation.</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with Hb measurement at 36-38 weeks gestation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Severe Maternal Anemia (Hemoglobin [Hb] &lt;8 g/dL) at 36-38 Weeks of Gestation</title>
          <description>Severe maternal anemia was defined as Hb &lt;8 g/dL.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with Hb measurement at 36-38 weeks gestation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1222"/>
                <count group_id="O2" value="1299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="1.05" upper_limit="2.55"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.24" upper_limit="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7035</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.90</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.2866</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Maternal Anemia (Hb &lt;11 g/dL) at 36-38 Weeks of Gestation</title>
        <description>Anemia was defined as Hb &lt;11 g/dL.</description>
        <time_frame>At 36-38 weeks of gestation.</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with Hb measurement at 36-38 weeks gestation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Maternal Anemia (Hb &lt;11 g/dL) at 36-38 Weeks of Gestation</title>
          <description>Anemia was defined as Hb &lt;11 g/dL.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with Hb measurement at 36-38 weeks gestation.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1222"/>
                <count group_id="O2" value="1299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.57" lower_limit="47.77" upper_limit="53.37"/>
                    <measurement group_id="O2" value="49.11" lower_limit="46.39" upper_limit="51.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4605</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.0400</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Placental Parasitemia at Delivery</title>
        <description>Participants with placental parasitemia at delivery were diagnosed using Placental blood smear at birth from participants who deliver at hospital.</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with placental parasite counts at delivery.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Placental Parasitemia at Delivery</title>
          <description>Participants with placental parasitemia at delivery were diagnosed using Placental blood smear at birth from participants who deliver at hospital.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with placental parasite counts at delivery.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1019"/>
                <count group_id="O2" value="1076"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" lower_limit="3.92" upper_limit="6.67"/>
                    <measurement group_id="O2" value="5.67" lower_limit="4.29" upper_limit="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7105</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1817</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Placental Malaria at Delivery Based on Histology</title>
        <description>Participants positive for placental malaria at delivery were evaluated based on placental histology.</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with a histology parasite evaluation at delivery.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Placental Malaria at Delivery Based on Histology</title>
          <description>Participants positive for placental malaria at delivery were evaluated based on placental histology.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with a histology parasite evaluation at delivery.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1040"/>
                <count group_id="O2" value="1100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" lower_limit="3.51" upper_limit="6.11"/>
                    <measurement group_id="O2" value="5.73" lower_limit="4.36" upper_limit="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3468</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1842</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexually Transmitted Infection (STI) Episodes Per Participant</title>
        <description>Number of episodes of sexually transmitted infection episodes per participant were noted. The STI's including Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis, from first dose to delivery (diagnosis was based on clinical presentation and lab results).</description>
        <time_frame>Approximately 40 weeks of gestational age .</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Sexually Transmitted Infection (STI) Episodes Per Participant</title>
          <description>Number of episodes of sexually transmitted infection episodes per participant were noted. The STI's including Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis, from first dose to delivery (diagnosis was based on clinical presentation and lab results).</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with available data.</population>
          <units>Number of episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.11" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.17" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the mean difference is 0 (treatment group equality) versus not equal 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>Analysis based on an ANOVA model with model terms for treatment group and randomization stratification variable. A negative mean difference between treatment groups favors Azithromycin + Chloroquine (reduction in number of STIs).</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sub-optimal Pregnancy Outcome Including Neonatal Death and Congenital Malformation</title>
        <description>Sub-optimal pregnancy outcome including neonatal deaths and congenital malformations, defined as any of the following: live-borne neonate (singleton) with low birth-weight (or LBW for short, defined as live birth weight &lt;2,500g), premature birth (&lt;37 weeks), abortion (≤28 weeks), still birth (&gt;28 weeks), neonatal death, congenital malformation, lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
        <time_frame>Approximately 40 weeks of gestational age.</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Total Outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sub-optimal Pregnancy Outcome Including Neonatal Death and Congenital Malformation</title>
          <description>Sub-optimal pregnancy outcome including neonatal deaths and congenital malformations, defined as any of the following: live-borne neonate (singleton) with low birth-weight (or LBW for short, defined as live birth weight &lt;2,500g), premature birth (&lt;37 weeks), abortion (≤28 weeks), still birth (&gt;28 weeks), neonatal death, congenital malformation, lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Total Outcomes.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.51" lower_limit="26.18" upper_limit="30.84"/>
                    <measurement group_id="O2" value="26.51" lower_limit="24.23" upper_limit="28.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2265</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.08</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.0604</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 36-38 Weeks of Gestation in Hb Concentration.</title>
        <description>Change from Baseline to 36-38 weeks of gestation in Hb concentration was noted.</description>
        <time_frame>Baseline, at 36-38 weeks of gestation.</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 36-38 Weeks of Gestation in Hb Concentration.</title>
          <description>Change from Baseline to 36-38 weeks of gestation in Hb concentration was noted.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of participants with available data.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1221"/>
                <count group_id="O2" value="1298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.05" upper_limit="0.21"/>
                    <measurement group_id="O2" value="0.27" lower_limit="0.19" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the mean difference is 0 (treatment group equality) versus not equal 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0131</p_value>
            <p_value_desc>Analysis based on an ANCOVA model with model terms for baseline value, treatment group and randomization stratification variable.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Neonates With Congenital Abnormalities at Birth</title>
        <description>Neonates with congenital abnormalities at birth were noted.</description>
        <time_frame>Approximately 40 weeks of gestational age.</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of total live births.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Neonates With Congenital Abnormalities at Birth</title>
          <description>Neonates with congenital abnormalities at birth were noted.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of total live births.</population>
          <units>Percentage of neonates</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1140"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.34" upper_limit="3.04"/>
                    <measurement group_id="O2" value="2.44" lower_limit="1.56" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6978</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.90</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.2694</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its SE, with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Perinatal or Neonatal Deaths</title>
        <description>Percentage of perinatal or neonatal deaths were noted.</description>
        <time_frame>Day 28 after delivery.</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of total live births.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Perinatal or Neonatal Deaths</title>
          <description>Percentage of perinatal or neonatal deaths were noted.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of total live births.</population>
          <units>Percentage of neonates</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1140"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.34" upper_limit="3.04"/>
                    <measurement group_id="O2" value="1.85" lower_limit="1.08" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6542</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.14</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.2908</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its SE, with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birth Weight of Live Borne Neonate</title>
        <description>Birth weight of live borne neonates were calculated in grams.</description>
        <time_frame>Approximately 40 weeks of gestational age.</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of live births with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Birth Weight of Live Borne Neonate</title>
          <description>Birth weight of live borne neonates were calculated in grams.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 was considered the first dose of study medication), and who had a single fetus. N=Number of live births with available data.</population>
          <units>grams</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1138"/>
                <count group_id="O2" value="1188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3148.3" lower_limit="3120" upper_limit="3176"/>
                    <measurement group_id="O2" value="3146.2" lower_limit="3119" upper_limit="3174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the mean difference is 0 (treatment group equality) versus not equal 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9145</p_value>
            <p_value_desc>Analysis based on an ANOVA model with model terms for treatment group and randomization stratification variable.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.5</ci_lower_limit>
            <ci_upper_limit>40.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Symptomatic Malaria Per Participant From First Intermittent Preventive Treatment of Falciparum Dose to Delivery</title>
        <description>This outcome measure determined if an episode of malaria started within the time period of first dose to delivery. Clinical episode of malaria was determined if the participant presented with clinical symptoms of malaria (fever &gt;37.5°C, oral) and diagnosed (either by rapid diagnostic tests or microscopy) with malaria.</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Symptomatic Malaria Per Participant From First Intermittent Preventive Treatment of Falciparum Dose to Delivery</title>
          <description>This outcome measure determined if an episode of malaria started within the time period of first dose to delivery. Clinical episode of malaria was determined if the participant presented with clinical symptoms of malaria (fever &gt;37.5°C, oral) and diagnosed (either by rapid diagnostic tests or microscopy) with malaria.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus.</population>
          <units>Number of episodes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0.04" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.11" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the mean difference is 0 (treatment group equality) versus not equal 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Analysis based on an ANOVA model with model terms for treatment group and randomization stratification variable. A negative mean difference between treatment groups favors Azithromycin + Chloroquine (reduction in number of symptomatic malaria).</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Additional Treatment for Symptomatic Malaria From First Dose to Delivery</title>
        <description>This outcome measure evaluated the participants requiring additional treatments for malaria during the study period following the first dose (diagnosed based on clinical presentation and/or lab test results).</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Additional Treatment for Symptomatic Malaria From First Dose to Delivery</title>
          <description>This outcome measure evaluated the participants requiring additional treatments for malaria during the study period following the first dose (diagnosed based on clinical presentation and/or lab test results).</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" lower_limit="4.54" upper_limit="6.94"/>
                    <measurement group_id="O2" value="10.52" lower_limit="8.94" upper_limit="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.49</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1221</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Peripheral Parasitemia at 36-38 Weeks of Gestation</title>
        <description>This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at 36-38 weeks of gestation. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
        <time_frame>At 36-38 weeks of gestation</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N = Number of participants with peripheral blood smear parasite counts at 36-38 weeks of gestation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Peripheral Parasitemia at 36-38 Weeks of Gestation</title>
          <description>This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at 36-38 weeks of gestation. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N = Number of participants with peripheral blood smear parasite counts at 36-38 weeks of gestation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1069"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" lower_limit="1.74" upper_limit="3.68"/>
                    <measurement group_id="O2" value="4.38" lower_limit="3.19" upper_limit="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0360</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.62</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.2295</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its SE, with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Peripheral Parasitemia at Delivery</title>
        <description>This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N = Number of participants with peripheral blood smear parasite counts at delivery.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Peripheral Parasitemia at Delivery</title>
          <description>This outcome measure evaluated the percentage of participants positive for peripheral parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N = Number of participants with peripheral blood smear parasite counts at delivery.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1025"/>
                <count group_id="O2" value="1086"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" lower_limit="4.59" upper_limit="7.51"/>
                    <measurement group_id="O2" value="7.46" lower_limit="5.90" upper_limit="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1975</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1630</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cord Blood Parasitemia at Delivery</title>
        <description>This outcome measure evaluated the percentage of participants positive for cord blood parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N = Number of participants with cord blood smear parasite counts at delivery.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cord Blood Parasitemia at Delivery</title>
          <description>This outcome measure evaluated the percentage of participants positive for cord blood parasitemia at delivery. A participant was positive for parasitemia if the number of asexual parasites per μL was &gt;0.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N = Number of participants with cord blood smear parasite counts at delivery.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1015"/>
                <count group_id="O2" value="1072"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.06" upper_limit="0.92"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.23" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4655</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.66</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.5675</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its SE, with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sexually Transmitted Infections From First Dose to 36-38 Weeks of Gestation</title>
        <description>Sexual transmitted disease included Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis infections. This was diagnosed based on clinical presentation prior to Week 36-38 and/or lab test results between Week 36-38.</description>
        <time_frame>Upto 36-38 weeks of gestation</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sexually Transmitted Infections From First Dose to 36-38 Weeks of Gestation</title>
          <description>Sexual transmitted disease included Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis infections. This was diagnosed based on clinical presentation prior to Week 36-38 and/or lab test results between Week 36-38.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.32" lower_limit="10.63" upper_limit="14.01"/>
                    <measurement group_id="O2" value="16.47" lower_limit="14.56" upper_limit="18.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.0918</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Chlamydia Trachomatis Infection at 36-38 Weeks of Gestation</title>
        <description>Participants positive for Chlamydia trachomatis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis.</description>
        <time_frame>At 36-38 weeks of gestation</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with lab test results at 36-38 weeks of gestation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Chlamydia Trachomatis Infection at 36-38 Weeks of Gestation</title>
          <description>Participants positive for Chlamydia trachomatis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with lab test results at 36-38 weeks of gestation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="746"/>
                <count group_id="O2" value="794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="0.61" upper_limit="2.33"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.08" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1113</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.34</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.5338</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>6.66</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Neisseria Gonorrhoeae Infection at 36-38 Weeks of Gestation</title>
        <description>Participants positive for Neisseria gonorrhoeae infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis.</description>
        <time_frame>At 36-38 weeks of gestation</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with laboratory test results at 36-38 weeks of gestation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Neisseria Gonorrhoeae Infection at 36-38 Weeks of Gestation</title>
          <description>Participants positive for Neisseria gonorrhoeae infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected and PCR assay was used for analysis.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with laboratory test results at 36-38 weeks of gestation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="746"/>
                <count group_id="O2" value="794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.00" upper_limit="0.85"/>
                    <measurement group_id="O2" value="1.64" lower_limit="0.76" upper_limit="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0284</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.6386</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treponema Pallidum Infection at 36-38 Weeks of Gestation</title>
        <description>Participants positive for Treponema pallidum infection was diagnosed based on laboratory result at 36-38 weeks of gestation. Treponema Pallidum particle Agglutination Assay was used.</description>
        <time_frame>At 36-38 weeks of gestation</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with laboratory test results at 36-38 weeks of gestation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treponema Pallidum Infection at 36-38 Weeks of Gestation</title>
          <description>Participants positive for Treponema pallidum infection was diagnosed based on laboratory result at 36-38 weeks of gestation. Treponema Pallidum particle Agglutination Assay was used.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with laboratory test results at 36-38 weeks of gestation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="751"/>
                <count group_id="O2" value="797"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.24" upper_limit="1.62"/>
                    <measurement group_id="O2" value="2.01" lower_limit="1.04" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0188</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.46</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.3291</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Trichomonas Vaginalis Infection at 36-38 Weeks of Gestation</title>
        <description>Participants positive for Trichomonas vaginalis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the laboratory test.</description>
        <time_frame>At 36-38 weeks of gestation</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with laboratory test results at 36-38 weeks of gestation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Trichomonas Vaginalis Infection at 36-38 Weeks of Gestation</title>
          <description>Participants positive for Trichomonas vaginalis infection was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the laboratory test.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with laboratory test results at 36-38 weeks of gestation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1068"/>
                <count group_id="O2" value="1143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.24" lower_limit="6.59" upper_limit="9.89"/>
                    <measurement group_id="O2" value="10.67" lower_limit="8.88" upper_limit="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0527</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.77</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1336</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Bacterial Vaginosis Infection at 36-38 Weeks of Gestation.</title>
        <description>Bacterial vaginosis was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the Gram staining.</description>
        <time_frame>At 36-38 weeks of gestation</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with laboratory test results at 36-38 weeks of gestation.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Bacterial Vaginosis Infection at 36-38 Weeks of Gestation.</title>
          <description>Bacterial vaginosis was diagnosed based on laboratory result at 36-38 weeks of gestation. A vaginal swab was collected for the Gram staining.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with laboratory test results at 36-38 weeks of gestation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="746"/>
                <count group_id="O2" value="794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" lower_limit="6.57" upper_limit="10.59"/>
                    <measurement group_id="O2" value="11.84" lower_limit="9.59" upper_limit="14.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0384</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.1536</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Neonates With Ophthalmia Neonatorum at Birth Period</title>
        <description>Ophthalmia neonatorum was diagnosed at birth. The laboratory diagnosis was performed among neonates with purulent discharge.</description>
        <time_frame>Approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Total live births.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Neonates With Ophthalmia Neonatorum at Birth Period</title>
          <description>Ophthalmia neonatorum was diagnosed at birth. The laboratory diagnosis was performed among neonates with purulent discharge.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Total live births.</population>
          <units>Percentage of neonates</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1140"/>
                <count group_id="O2" value="1190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.01" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.00" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3942</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.09</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.8648</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>11.38</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Bacterial Infections Including Pneumonia and Other Lower Respiratory Tract Infections From First Dose to Delivery</title>
        <description>Participants positive for bacterial infections including other lower respiratory tract infections were measured anytime from first dose administration to delivery.</description>
        <time_frame>Up to approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Bacterial Infections Including Pneumonia and Other Lower Respiratory Tract Infections From First Dose to Delivery</title>
          <description>Participants positive for bacterial infections including other lower respiratory tract infections were measured anytime from first dose administration to delivery.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participants with available data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.13" upper_limit="0.84"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.67" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0332</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.39</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.4439</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-eclampsia From Week 20 to Delivery</title>
        <description>Pre-eclampsia was diagnosed as systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg on two separate readings taken at least 4 hours apart and proteinuria at least 300 mg protein in a 24 hour urine collection.</description>
        <time_frame>From Week 20 to approximately 40 weeks of gestational age</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N= Number of participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-eclampsia From Week 20 to Delivery</title>
          <description>Pre-eclampsia was diagnosed as systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least 90 mmHg on two separate readings taken at least 4 hours apart and proteinuria at least 300 mg protein in a 24 hour urine collection.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N= Number of participants with available data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1440"/>
                <count group_id="O2" value="1443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.22" upper_limit="1.03"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.51" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 2-sided P-value tests the null hypothesis that the relative risk equals 1 (treatment group equality) versus not equal 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2321</p_value>
            <p_value_desc>Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint).</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.61</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.4195</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>The estimated risk ratio is presented along with its standard error (SE), with the SE on the log(e) scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasopharyngeal Swabs Positive for Macrolide Resistant Streptococcus Pneumoniae</title>
        <description>This outcome measure evaluated the Streptococcus pneumoniae sensitivity against macrolide antibiotics.</description>
        <time_frame>Visits 6 and 7</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participant with nasopharyngeal swabs isolating Streptococcus pneumoniae at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Nasopharyngeal Swabs Positive for Macrolide Resistant Streptococcus Pneumoniae</title>
          <description>This outcome measure evaluated the Streptococcus pneumoniae sensitivity against macrolide antibiotics.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participant with nasopharyngeal swabs isolating Streptococcus pneumoniae at the specified visit.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 6 (N = 8 and 17 respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (N = 16 and 11 respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for Visit 6 presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Not specified</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Not specified</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.76</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for Visit 7 presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Not specified</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Not specified</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasopharyngeal Swabs Positive for Penicillin Resistant Streptococcus Pneumoniae</title>
        <description>This outcome measure evaluated the Streptococcus pneumoniae sensitivity against penicillin antibiotics.</description>
        <time_frame>Visits 6 and 7</time_frame>
        <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participant with nasopharyngeal swabs isolating Streptococcus pneumoniae at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Azithromycin + Chloroquine</title>
            <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
          <group group_id="O2">
            <title>Sulfadoxine + Pyrimethamine</title>
            <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Nasopharyngeal Swabs Positive for Penicillin Resistant Streptococcus Pneumoniae</title>
          <description>This outcome measure evaluated the Streptococcus pneumoniae sensitivity against penicillin antibiotics.</description>
          <population>ITT set was used which consisted of participants who were randomized, received at least one dose of study medication (Day 0 at Visit 1 is considered the first dose of study medication), and who had a single fetus. N=Number of participant with nasopharyngeal swabs isolating Streptococcus pneumoniae at the specified visit.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1445"/>
                <count group_id="O2" value="1445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 6 (N = 8 and 17 respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7 (N = 16 and 11 respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for Visit 6 presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Not specified</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for Visit 7 presented above.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Not specified</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Visit 7 (6 months post last dose). Includes data up to 35 days after last dose of study drug for mothers (treatment emergent), and includes all data for neonates.</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. Some events are seen only in neonates (e.g neonatal malformation/anomalies, LBW etc.) and are not expected in mothers and vice versa. Such events are designated as ‘zero’ in the respective ‘familial status- neonate/mother’ in the below table.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mother (Azithromycin + Chloroquine)</title>
          <description>The participants received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
        </group>
        <group group_id="E2">
          <title>Mother (Sulfadoxine + Pyrimethamine)</title>
          <description>The participants received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
        </group>
        <group group_id="E3">
          <title>Neonate (Azithromycin + Chloroquine)</title>
          <description>Live births of participants who received 1000 mg Azithromycin (AZ) and 620 mg of Chloroquine (CQ) base (4 combination tablets of AZCQ with individual strength of 250 mg/155 mg), by mouth once daily for 3 days (Days 0, 1, 2) per treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
        </group>
        <group group_id="E4">
          <title>Neonate (Sulfadoxine + Pyrimethamine)</title>
          <description>Live births of participants who received sulfadoxine-pyrimethamine (SP) (Fansidar) treatment course: 1500 mg sulfadoxine and 75 mg pyrimethamine (3 fixed tablets of SP strength at 500 mg/25 mg), single oral dose on Day 0 of each treatment. There were a total of 3 treatments at 4-8 week intervals.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Haemorrhagic disease of newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tricuspid valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Anal atresia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Cerebellar hypoplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Congenital hand malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Congenital malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Congenital umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Cystic lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Dysmorphism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Exomphalos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Hypospadias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Microgenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Polydactyly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Necrotising colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Rectourethral fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Death neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Neonatal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Uterine rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Apgar score low</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>HIV test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>HELLP syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Haemorrhage in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Low birth weight baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Neonatal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Obstructed labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Placental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Placental infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Preterm premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Umbilical cord around neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Renal vessel disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Neonatal aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1177" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="888" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="301" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="326" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="650" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="116" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Perineal injury</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="460" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="300" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Low birth weight baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1446"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1149"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This program was terminated by Pfizer based on the results of the pre-planned interim analysis for this pivotal study. The interim analysis showed no benefit of the study drug (AZCQ) compared to standard of care (SP).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

